Researchers designing a treatment for coronavirus are creating artificial antibodies that neutralise SARS-CoV-2 and prevent infection,media BGR reported. Sorrento, one of the companies involved in the development of monoclonal antibody therapy, recently announced that it is proposing an antibody that could be tested in the lab and a new coronavirus. The pharmaceutical company revealed that it has a second compound that suppresses the virus under laboratory conditions, a protein called STI-4398 (COVIDTRAP).
Sorrento announced a few weeks ago that one of its candidate antibodies would prevent new coronavirus infections with cells. The company had a similar finding, saying it had a second compound that could stop infection in laboratory tests. The new candidate drug, called STI-4398, will be used in a future Sorrento drug called COVIDTRAP. It is a proprietary ACE2 (angiotensin conversion enzyme 2)-Fc fusion protein that produces a “soluble SARS-CoV-2 virus binding bait receptor protein” that binds to the S protein of the new coronavirus. The idea is to block the link between SARS-CoV-2 and human cells, and to moderate infection. Without infecting cells, a single copy of the virus cannot reproduce itself, and the immune system can remove pathogens more quickly.
Sorrento announced Friday that STI-4398 completely inhibits the ability of the new coronavirus infection in African green monkey renal epithelial cells (VERO/E6) at low concentrations.
“StI-4398 COVIDTRAP protein and STI-1499 neutral antibodies have shown efficacy in the SARS-CoV-2 in vitro cell infection model established in our laboratory, and these results justify progression into animal research. Dr Slobodan Paessler said: “We plan to submit all preclinical data for scientific publication within the next two to three months. “
The company has discussed the new drug with the U.S. Food and Drug Administration (FDA) and has received clinical trial guidance for STI-4398, COVIDTRAP, for the treatment of infected patients and preventive use.